AIDS and HIV Therapy
Rapid viral resistance seen in response to fusion inhibitor treatment
Published in AIDS Weekly, July 22nd, 2002
"The synthetic peptide T-20 (enfuvirtide) represents the first of a new class of antiretroviral compounds to demonstrate in vivo potency by targeting a step in viral entry," explained Xiping Wei and colleagues at the University of Alabama at Birmingham and the Birmingham Veterans Affairs Medical Center. "T-20 inhibits a conformational change in the human immunodeficiency virus type 1 (HIV-1) transmembrane glycoprotein (gp41) that is required for fusion between HIV-1 and target cell...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
Source: AIDS Weekly (2002-07-22)
More Articles from AIDS Weekly
- AIDS and HIV Therapy
P-glycoprotein inhibitors can increase antiretroviral CNS delivery - Antiretrovial Therapy
Successful antiretroviral treatment has little effect on overall immune function - AIDS and HIV Pathogenesis
Noncytotoxic antiviral mechanisms contribute to persistent infection resistance - AIDS and HIV Therapy
Interleukin-7 increases risk of naive T-cell infection - AIDS and HIV Therapy
Isotretinoin has little impact on cervical cancer risk - Cachexia
Loss of lean body mass in HIV-infected men linked to immunological processes - More from this issue of AIDS Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
